Asymchem Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
10,617
- Stock Symbol
-
002821
- Investments
-
7
- Share Price
-
$20.49
- (As of Friday Closing)
Asymchem General Information
Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
Contact Information
Website
www.asymchem.comCorporate Office
- Number 6 Dongting 3rd Avenue
- TEDA
- Tianjin, 300457
- China
Corporate Office
- Number 6 Dongting 3rd Avenue
- TEDA
- Tianjin, 300457
- China
Asymchem Stock Performance
As of 20-Nov-2026, Asymchem’s stock price is $20.49. Its current market cap is $7.21B with 362M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.49 | $21.18 | $12.44 - $29.54 | $7.21B | 362M | 8.9M | $0.48 |
Asymchem Financials Summary
As of 30-Sep-2026, Asymchem has a trailing 12-month revenue of $1.08B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,077,212 | 3,642,051 | 2,766,343 | 4,636,396 |
| Revenue | 1,078,713 | 927,532 | 808,960 | 1,106,053 |
| EBITDA | 172,432 | 229,029 | 191,486 | 405,215 |
| Net Income | 171,850 | 157,491 | 132,249 | 320,685 |
| Total Assets | 3,227,157 | 2,898,147 | 2,642,232 | 2,788,584 |
| Total Debt | 102,842 | 44,190 | 44,486 | 20,773 |
Asymchem Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Asymchem Comparisons
Industry
Financing
Details
Asymchem Competitors (21)
One of Asymchem’s 21 competitors is Shanghai Medicilon, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Shanghai Medicilon | Formerly VC-backed | Shanghai, China | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| ChemPartner | Formerly PE-Backed | Shanghai, China | ||||
| Sino Biological | Formerly VC-backed | Beijing, China | ||||
| Halloran Consulting Group | Private Equity-Backed | Cambridge, MA |
Asymchem Patents
Asymchem Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026065641-A1 | Yarrowia lipolytica yl590 and use thereof | Pending | 29-Sep-2024 | ||
| WO-2026020564-A1 | Preparation method for saccharopolyspora spinosa spn016 and spinosad and screening method for saccharopolyspora spinosa | Pending | 25-Jul-2024 | ||
| WO-2026011779-A1 | Method for preparing cemdisiran | Pending | 10-Jul-2024 | ||
| WO-2026011783-A1 | Method for preparing givosiran | Pending | 10-Jul-2024 | ||
| WO-2026011784-A1 | Method for preparing lumasiran | Pending | 10-Jul-2024 | C12P19/34 |
Asymchem Signals
Asymchem Investments & Acquisitions (7)
Asymchem’s most recent deal was a Later Stage VC with Xellsmart. The deal was made on 14-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xellsmart | 14-Jan-2026 | Later Stage VC | Drug Discovery | ||
| Pfizer (Research and Development Laboratory and Production Workshops in Sandwich, England) | 22-May-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Bio-Link (Medical Supplies) | 01-Nov-2023 | Early Stage VC | Medical Supplies | ||
| Snapdragon Chemistry | 09-Sep-2022 | Merger/Acquisition | BPO/Outsource Services | ||
| Yipu Kenuo | 17-Dec-2021 | Merger/Acquisition | Other Healthcare Technology Systems |
Asymchem ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
16.7 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Asymchem Exits (4)
Asymchem’s most recent exit was on 01-Nov-2023 from Bio-Link (Medical Supplies). The exit was categorized as with 10 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bio-Link (Medical Supplies) | 01-Nov-2023 | Completed |
|
||
| Guanqin Pharmaceutical | 15-Sep-2020 | Completed |
|
||
| Snapdragon Chemistry | 02-Sep-2020 | Corporate | Completed |
Asymchem Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| AsymBio | Shanghai, China | 2022 | |
| Tianjin Youji Medical | Tianjin, China | 2020 | |
| Yipu Kenuo | Beijing, China | 2015 |
Asymchem FAQs
-
When was Asymchem founded?
Asymchem was founded in 1999.
-
Where is Asymchem headquartered?
Asymchem is headquartered in Tianjin, China.
-
What is the size of Asymchem?
Asymchem has 10,617 total employees.
-
What industry is Asymchem in?
Asymchem’s primary industry is Biotechnology.
-
Is Asymchem a private or public company?
Asymchem is a Public company.
-
What is Asymchem’s stock symbol?
The ticker symbol for Asymchem is 002821.
-
What is the current stock price of Asymchem?
As of 20-Nov-2026 the stock price of Asymchem is $20.49.
-
What is the current market cap of Asymchem?
The current market capitalization of Asymchem is $7.21B.
-
What is Asymchem’s current revenue?
The trailing twelve month revenue for Asymchem is $1.08B.
-
Who are Asymchem’s competitors?
Shanghai Medicilon, Biocon, ChemPartner, Sino Biological, and Halloran Consulting Group are some of the 21 competitors of Asymchem.
-
What is Asymchem’s annual earnings per share (EPS)?
Asymchem’s EPS for 12 months was $0.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process